Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric/young adult glofitamab with or without chemoimmunotherapy for relapsed/refractory mature B-cell non-Hodgkin lymphoma
jRCT2031260512Phase 2Not yet recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2027
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in mature B-cell lymphoma, Burkitt lymphoma (BL), Not applicable - non-specific umbrella term and 2 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Complete response rate, Safety and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)Not applicable - non-specific umbrella termdiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on jRCT2031260512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260512.